March 06, 2026 — Wilmington, Delaware, USA
Global biopharmaceutical innovator Incyte has announced that the European Commission has approved Zynyz in combination with platinum-based chemotherapy for the first-line treatment of adults with advanced squamous cell carcinoma of the anal canal (SCAC). This regulatory decision represents a major advancement in the treatment of a rare but increasingly recognized cancer and introduces the first systemic PD-1 immunotherapy regimen approved in Europe for this indication. The approval follows compelling clinical data demonstrating that the addition of Zynyz to chemotherapy significantly improves disease outcomes compared with standard chemotherapy alone, highlighting the growing importance of immunotherapy-based cancer treatments in modern oncology care.
Phase 3 Trial Demonstrates Significant Clinical Benefit
The European Commission approval was primarily based on results from the Phase 3 POD1UM-303/InterAACT-2 clinical trial, which evaluated the safety and efficacy of retifanlimab combined with carboplatin and paclitaxel chemotherapy in adult patients with metastatic or inoperable locally recurrent SCAC who had not previously received systemic chemotherapy. The study demonstrated that patients receiving the Zynyz plus chemotherapy combination experienced a statistically significant improvement in progression-free survival compared with chemotherapy alone, representing an important therapeutic advancement for this rare malignancy.
Clinical trial data showed a 37% reduction in the risk of disease progression or death among patients treated with the combination therapy. Patients receiving the Zynyz regimen achieved a median progression-free survival of 9.3 months, compared with 7.4 months for patients receiving chemotherapy alone. The trial also demonstrated clinically meaningful improvements in additional efficacy measures, including overall survival and other secondary endpoints. Importantly, investigators reported no unexpected safety signals, and the safety profile of the therapy remained consistent with other PD-1 inhibitor and chemotherapy combination treatments used in oncology.
Although some serious adverse reactions were observed in approximately 47% of patients receiving the combination therapy, these outcomes were considered manageable and aligned with known side effects associated with immunotherapy-chemotherapy regimens. The most frequently reported serious adverse reactions included sepsis, pulmonary embolism, diarrhea, and vomiting, all of which were consistent with previously reported safety findings in similar clinical studies.
Advertisement
Expanding Treatment Options for a Rare Cancer
Squamous cell carcinoma of the anal canal represents approximately 85% of all anal cancer cases worldwide, though the disease itself remains relatively rare. Despite its rarity, the incidence of SCAC has been steadily increasing globally, with estimates suggesting an annual growth rate of roughly 3 percent in reported cases. Risk factors associated with the disease include human papillomavirus (HPV) infection, which accounts for nearly 90% of cases, as well as immunocompromised conditions such as HIV infection, which significantly increases the likelihood of developing the disease.
Because early symptoms of SCAC often resemble common benign conditions such as hemorrhoids—including pain, itching, swelling, and changes in bowel function—many patients are diagnosed at later stages when the disease has already progressed. As a result, advanced or metastatic disease remains challenging to treat, and treatment advances have historically been limited. The approval of Zynyz therefore represents a major breakthrough for clinicians and patients by introducing a new immunotherapy option that expands the standard of care for this rare cancer.
Immunotherapy Innovation Driving Oncology Progress
Zynyz (retifanlimab) is a humanized monoclonal antibody designed to target the programmed death-1 (PD-1) immune checkpoint receptor, a key regulatory pathway that tumors often exploit to evade immune system detection. By blocking this pathway, the therapy helps restore immune system activity against cancer cells, enabling the body to recognize and destroy malignant cells more effectively.
The approval further expands the therapeutic reach of Zynyz in Europe, where it had previously received authorization as a monotherapy treatment for metastatic or recurrent Merkel cell carcinoma, another rare but aggressive cancer. The latest regulatory milestone demonstrates Incyte’s continued commitment to advancing immuno-oncology therapies designed to address unmet medical needs in rare cancers and difficult-to-treat tumors.
With ongoing clinical trials within the POD1UM clinical development program, which includes several Phase 1, Phase 2, and Phase 3 studies evaluating retifanlimab across multiple solid tumor indications, researchers remain optimistic that PD-1 targeted immunotherapies will continue to reshape cancer treatment strategies worldwide.
As immunotherapy technologies continue to evolve, breakthroughs such as the approval of Zynyz for advanced anal cancer underscore how innovative biopharmaceutical research can deliver meaningful progress for patients facing rare and historically underserved diseases.
z
Source: Incyte press release
